Binimetinib is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib.

Melanoma

Indicated in combination with encorafenib for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test

45 mg PO BID in combination with encorafenib until disease progression or unacceptable toxicity

See encorafenib drug monograph for recommended dosing information

Non-Small Cell Lung Cancer

Indicated in combination with encorafenib for patients with unresectable or metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test

45 mg PO BID in combination with encorafenib until disease progression or unacceptable toxicity

See encorafenib drug monograph for recommended dosing information